Evaluations of buparvaquone as a treatment for equine babesiosis (Babesia equi).
We evaluated the efficacy of buparvaquone in eliminating Babesia equi of European origin in carrier horses and in experimentally infected splenectomized ponies. When administered at the rate of 2.5 mg/kg of body weight, IM, 4 times at 96-hour intervals, buparvaquone was effective in eliminating B equi carrier infection in 1 horse. Such results could not be repeated at the same dosage or at 3.5 or 5 mg/kg, IM. Buparvaquone given at the rate of 4 to 6 mg/kg IV and/or IM was therapeutically effective in 4 of 5 acute B equi infections in splenectomized ponies. The treated ponies became carriers.
Zaugg
J L
JL
Veterinary Teaching and Research Center, University of Idaho, Caldwell 83605.
Lane
V M
VM
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D001404:Babesiosis / Q000188:drug therapy*; D002353:Carrier State / Q000188:drug therapy / Q000662:veterinary*; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D008297:Male; D009285:Naphthoquinones / Q000627:therapeutic use*; D013156:Splenectomy / Q000662:veterinary; D013997:Time Factors
D000981:Antiprotozoal Agents; D009285:Naphthoquinones; C046326:buparvaquone